UPDATED May 15, 2024
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
TVTX | US$6.80 | -0.3% | -60.3% | US$510.1m | US$14.86 | PS3.3x | E67.7% | n/a | Pharmaceuticals & Biotech | ||
KALV | US$12.01 | -0.4% | 16.7% | US$526.9m | US$29.80 | PB5.7x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
VRCA | US$9.10 | 19.6% | 54.5% | US$402.6m | US$14.17 | PS43.3x | E65.9% | n/a | Pharmaceuticals & Biotech | ||
ASLE | US$7.71 | 2.1% | -51.5% | US$422.5m | US$10.50 | PE576.4x | E106.1% | n/a | Capital Goods | ||
PPSI | US$4.14 | 2.5% | -24.5% | US$39.7m | US$10.50 | PE23.2x | E37.6% | n/a | Capital Goods | ||
AUNA | US$8.77 | 18.4% | n/a | US$638.6m | US$16.05 | PB1.6x | E45.4% | n/a | Healthcare | ||
YSG | US$4.35 | 0.7% | -0.4% | US$488.0m | US$4.35 | PB0.8x | E120.5% | n/a | Household | ||
OPNT | US$20.65 | -1.3% | -22.3% | US$108.8m | US$21.50 | PS4.9x | E62.6% | n/a | Pharmaceuticals & Biotech | ||
DCTH | US$7.19 | 30.4% | 10.3% | US$196.4m | US$21.20 | PS96.7x | E62.2% | n/a | Healthcare | ||
ECOR | US$7.40 | 2.2% | 16.7% | US$45.0m | US$23.16 | PS2.1x | E66.9% | n/a | Healthcare | ||
MDGL | US$211.73 | 1.8% | -23.8% | US$4.5b | US$363.86 | PB5.3x | E64.3% | n/a | Pharmaceuticals & Biotech | ||
AXSM | US$75.93 | 0.3% | -3.3% | US$3.7b | US$123.56 | PS14.4x | E65.1% | n/a | Pharmaceuticals & Biotech | ||
ARQT | US$9.24 | 15.2% | -2.2% | US$1.1b | US$18.50 | PS10.1x | E65.2% | n/a | Pharmaceuticals & Biotech | ||
HRMY | US$29.70 | -6.3% | -16.4% | US$1.7b | US$42.25 | PE12.2x | E28.4% | n/a | Pharmaceuticals & Biotech | ||
ALDX | US$4.17 | 2.5% | -57.7% | US$247.8m | US$9.25 | PB2.2x | E61.1% | n/a | Pharmaceuticals & Biotech | ||
ARDX | US$7.85 | -7.4% | 99.7% | US$1.8b | US$13.83 | PS11.5x | E60.7% | n/a | Pharmaceuticals & Biotech | ||
INNV | US$4.00 | -6.1% | -37.4% | US$546.7m | US$6.00 | PB1.9x | E123.5% | n/a | Healthcare | ||
IMAX | US$17.62 | 6.1% | -8.9% | US$930.9m | US$22.25 | PE35.5x | E27.3% | n/a | Media | ||
SLNO | US$45.21 | -2.3% | 951.4% | US$1.6b | US$68.14 | PB11.5x | E61.5% | n/a | Pharmaceuticals & Biotech | ||
EOLS | US$13.24 | -0.2% | 34.0% | US$799.5m | US$22.29 | PS3.8x | E66.4% | n/a | Pharmaceuticals & Biotech | ||
COMP | US$4.41 | 34.5% | 9.7% | US$2.1b | US$4.15 | PB6.6x | E86.0% | n/a | Real Estate Management and Development | ||
IRWD | US$6.56 | -19.2% | -35.7% | US$1.1b | US$16.33 | PS2.5x | E76.2% | n/a | Pharmaceuticals & Biotech | ||
BRDG | US$7.88 | 13.5% | -12.4% | US$895.9m | US$9.88 | PB0.6x | E98.0% | 8.4% | Diversified Financials | ||
GAME | US$1.39 | -13.1% | -67.0% | US$42.1m | US$5.00 | PB2.3x | E100.9% | n/a | Media |